Development of antibodies to human thrombin and factor V in a pediatric patient exposed to topical bovine thrombin

Pediatric Blood and Cancer

Volumn 55, Issue 6, 2010, Pages 1195-1197

  Lo, Clara Y ^a   Jones, Carol ^b   Glader, Bertil ^a   Zehnder, James L ^a,b  

^a STANFORD UNIVERSITY   (United States)

^b STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Coagulation; Hematology; Hemostasis and thrombosis; Thrombotic disorders

Indexed keywords

BLOOD CLOTTING FACTOR 5; BLOOD CLOTTING FACTOR 5 ANTIBODY; FRESH FROZEN PLASMA; IMMUNOGLOBULIN; METHYLPREDNISOLONE; PROTEIN ANTIBODY; PROTHROMBIN; PROTHROMBIN ANTIBODY; STEROID; THROMBIN; THROMBIN JMI; UNCLASSIFIED DRUG; VITAMIN K GROUP;

ANTIBODY TITER; AORTOPULMONARY SHUNT; ARTICLE; AUTOIMMUNE DISEASE; BLEEDING; BLOOD CLOTTING DISORDER; CASE REPORT; CHILD; CYANOSIS; DRUG DOSE REDUCTION; ENDOTRACHEAL TUBE; FATIGUE; HEMOSTASIS; HUMAN; LABORATORY TEST; LIVER DYSFUNCTION; MALE; NASOGASTRIC TUBE; PARTIAL THROMBOPLASTIN TIME; POSTOPERATIVE CARE; POSTOPERATIVE HEMORRHAGE; PRESCHOOL CHILD; PRIORITY JOURNAL; PROTHROMBIN TIME; PULMONARY ARTERY; STENT; THORAX SURGERY; THROMBIN TIME;

ADMINISTRATION, TOPICAL; ANIMALS; BLOOD COAGULATION DISORDERS; BLOOD COAGULATION FACTORS; CATTLE; CHILD, PRESCHOOL; FACTOR V; HEMORRHAGE; HUMANS; IMMUNOGLOBULIN G; IMMUNOGLOBULINS, INTRAVENOUS; MALE; PROGNOSIS; PROTHROMBIN TIME; THROMBIN; THROMBIN TIME; THROMBOPLASTIN;

EID: 77958558587     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.22699     Document Type: Article

References (14)

1. Winterbottom N, Kuo JM, Nguyen K, et al. Antigenic responses to bovine thrombin exposure during surgery: A prospective study of 309 patients. J Appl Res 2005; 2:
2. Streiff MB, Ness PM. Acquired FV inhibitors: A needless iatrogenic complication of bovine thrombin exposure. Transfusion 2002; 42: 18-26.
3. George S, Nagabhushana MS, Cyran EM. Coagulopathy due to an acquired Factor V inhibitor and subsequently thrombosis (letter). Am J Hematol 1995; 49: 98-100.
4. Rapaport SI, Ziveline A, et al. Clinical significance of antibodies to bovine and human thrombin and Factor V after surgical use of bovine thrombin. Am J Clin Path 1992; 97: 84-91.
5. Savage WJ, Kickler TS, Takemoto CM. Acquired coagulation factor inhibitors in children after topical bovine thrombin exposure. Pediatr Blood Cancer 2007; 49: 1025-1029.
6. Zehnder JL, Leung LL. Development of antibodies to thrombin and Factor V with recurrent bleeding in a patient exposed to topical bovine thrombin. Blood 1990; 76: 2011-2016.
7. Bannigner H, Hardegger T, Tobler A, et al. Fibrin glue in surgery: frequent development of inhibitors of bovine thrombin and human Factor V. Br J Haematol 1993; 85: 528-532.
8. Ortel TL, Mercer M, Thames E, et al. Immunologic impact and clinical outcomes after surgical exposure to bovine thrombin. Ann Surg 2001; 233: 88-96.
9. Spero JA. Bovine thrombin-induced inhibitor of Factor V and bleeding risk in postoperative neurosurgical patients. Report of three cases. J Neurosurg 1993; 78: 817-820.
10. Muntean W, Zenz W, Finding K, et al. Inhibitor to Factor V after exposure to fibrin sealant during cardiac surgery in a two-year-old child. Acta Paediatr 1994; 83: 84-87.
11. Ness P, Creer M, Rodgers GM, et al. Building an immune-mediated coagulopathy consensus: early recognition and evaluation to enhance post-surgical patient safety. Patient Saf Surg 2009; 3:
12. Tarantino MD, Ross MP, Daniels TM, et al. Modulation of an acquired coagulation Factor V inhibitor with intravenous immune globulin. J Pediatr Hematol Oncol 1997; 19: 226-231.
13. Crow SS, et al. Postoperative coagulopathy in a pediatric patient after exposure to bovine topical thrombin. Ann Thorac Surg 2007; 83: 1547-1549.
14. Kessler CM, Ortel TL. Recent developments in topical thrombins. Thromb Haemost 2009; 102: 15-24.